Previously we have shown that 20 days aft er the tumor cells injection smaller melanomas have been developed in chemically sympathectomized mice in comparison with animals having intact sympathetic nervous system. However, it is known that chemical sympathectomy reduces the sympathetic neurotransmission only temporarily. In the present study, we monitored the survival of the sympathectomized mice with melanoma with an attempt to fi nd out how long the suppressing eff ect of sympathectomy on the melanoma growth may endure.
Experimental and clinical studies have shown that exposure to stress may aff ect several crucial processes related to the tumor growth, e.g. potentiate the proliferation and migration of the cancer cells, inhibit the tumor cell apoptosis, increase the tumor cell invasiveness and metastatic activity, support the neoangiogenesis in the tumor tissue, or suppress the natural killer cell activity (Godbout and Glaser 2006; Sood et al. 2006; Th aker et al. 2006; Andersen et al. 2007; Sephton et al. 2009; Hassan et al. 2013; Nagaraja et al. 2013) . Th ese eff ects are mediated especially by neurotransmitters released by sympathetic nerve endings, particularly by norepinephrine (Yang 2010) . Norepinephrine may exert stimulatory eff ect on tumor growth by aff ecting the tumor microenvironment (e.g. suppressing the anti-tumor immunity and stimulating the vascular endothelial growth factor -VEGF) or binding directly on β-adrenergic receptors expressed by tumor cells with a consequent exaggeration of tumor cells proliferation and migration (Cole and Sood 2012) . Moreover, neuropeptide Y, a co-transmitter released from the sympathetic nerve endings, may exert stimulatory eff ect on the tumor growth as well (Tilan and Kitlinska 2010) .
Stimulatory eff ect of the sympathetic nervous system on the tumor growth and development of metastasis has been further supported by experimental and clinical studies, in which sympathetic neurotransmission was attenuated or eliminated (Raju et al. 2009; Sloan et al. 2010; Barron et al. 2011; Lackovicova et al. 2011; Magnon et al. 2013) . Based on these facts, it has been suggested that interventions reducing the eff ect of the sympathetic neurotransmitters may represent a potential adjuvant therapy in oncological patients (Schuller 2010; Powe and Entschladen 2011; Tang et al. 2013) . Th ese interventions may be useful also for the secondary micro metastasis development prevention aft er surgical extirpation of the primary tumor mass (Glasner et al. 2010; Neeman et al. 2012) . However, there is no consensus when exactly to start these interventions in oncological patients and how long it is necessary to attenuate sympathetic signalization in tumor tissue.
Previously we have shown that chemical sympathectomy, induced by 6-hydroxydopamine (6-OHDA) before tumor cells injection, signifi cantly reduced the tumor mass in mice sacrifi ced 20 days aft er the injection of melanoma cells (Horvathova et al. 2016 ). However, it is known that approximately within one month aft er 6-OHDA administration, the sympathetic nerve endings start to regenerate (Kruszewska et al. 1995) . Th erefore, in this study we investigated the long-term eff ect of chemical sympathectomy, performed before tumor growth induction, on the melanoma progression. Hence, sympathectomised mice were injected with melanoma cells and development of tumors, survival of tumor-bearing mice, and weight of developed melanomas, were analyzed. 
Material and Methods
Animals. Th e experiment was performed on 3 months-old male C57BL/6J mice. Th e mice, bred at the Institute of Experimental Endocrinology, were housed three to six per cage and kept under controlled conditions in the animal facility (12 h light/dark cycle, lights on at 06:00 AM; temperature 22±2 °C, humidity 55±10%) with free access to tap water and standard pelleted chow. Th e weight of mice at the beginning of experiment was in the range of 24-27 g. All experimental procedures were performed between 08:00-13:00 h to avoid the animals of all the external stressogen stimuli and were approved by the Animal Experimental protocol. Mice were randomly divided into two experimental groups based on the type of treatment (Figure 1 ): a) control mice with intact sympathetic nervous system injected later with tumor cells (VEH, n=25); b) sympathectomized mice injected later with tumor cells (6-OHDA, n=27).
Chemical sympathectomy was performed seven days before melanoma cells inoculation in conscious mice by intraperitoneal injection of neurotoxin 6-hydroxydopamine hydrobromide (6-OHDA, 100 mg/kg of body weight, Sigma-Aldrich, Germany) over two consecutive days (Figure 1 ). Th e 6-OHDA was dissolved in a sterile saline containing 0.1% of the antioxidant ascorbic acid (Sigma-Aldrich, Germany). Th is dose has been shown to induce destruction of sympathetic nerve endings aft er 3-5 days and this eff ect lasted for at least 21 days in spleen (Kruszewska et al. 1995) . Mice of VEH group were intraperitoneally injected with vehicle (sterile saline containing 0.1% of the antioxidant ascorbic acid). Th e effi ciency of the sympathectomy was confi rmed immediately aft er application of 6-OHDA by presence of ptosis in sympathectomized mice (Claude Bernard-Horner's syndrome) and blood in urine indicating the destruction of the sympathetic nerve endings in the urinary tract. Moreover, to confi rm the effi ciency of the sympathectomy, we determined norepinephrine concentrations in the spleen seven days aft er 6-OHDA administration (VEH: 2300.2±200.7 vs. 6-OHDA: 200.2±24.5 pg/mg of tissue; Figure 2 ).
One week aft er the administration of 6-OHDA or vehicle, all the mice were inoculated with the B16-F10 melanoma cells (Figure 1) . A B16-F10 melanoma cell suspension was injected subcutaneously as a single dose of 3x10 3 tumor cells in 0.1 ml of RPMI 1640 medium per mice without anesthesia. Before tumor cells inoculation, back of mice was shaven and disinfected. During the experiment, the health status of animals was monitored and mice were inspected daily for the presence of palpable tumor mass in the place of melanoma cells injection.
Th e mice of both the experimental groups were kept to determine the eff ect of the sympathetic denervation on the tumor incidence, progression, and survival of the tumor-bearing mice. Th e euthanasia time of these mice was determined based on their health status, especially the motor skills of mice and their capability to ingest were monitored. Th e last mouse with developed melanoma was euthanized on 78 th day aft er tumor cells injection. In two mice (from 6-OHDA group) no tumors developed. Th ey were euthanized on the 78 th day and examined for the presence of melanoma to confi rm the lack of tumor formation.
Statistical analysis. All statistical analyses were performed using SigmaPlot 11.0 (Systat Soft ware, Figure 2 . Th e eff ect of the chemical sympathectomy on the splenic norepinephrine concentration. Mice were injected with either 6-OHDA (6-OHDA; ; n=4) or an equal volume of vehicle (VEH;; n=4). Concentration of splenic norepinephrine was determined by ELISA assay. Each value is the mean±SEM. ***p<0.001. Abbreviation: 6-OHDA -6-hydroxydopamine, VEH -vehicle Percentage of the developed tumors in the sympathectomized mice (6-OHDA; -; n=27) and mice with the intact sympathetic nervous system (VEH; ---; n=25) injected by B16-F10 melanoma cells (A). Incidence of melanoma (%) aft er injection of B16-F10 melanoma cells in sympathectomized mice (6-OHDA; ; n=27) and mice with intact sympathetic nervous system (VEH; ; n=25) (B). Survival of the sympathectomized mice (6-OHDA; -; n=27) and mice with intact sympathetic nervous system (VEH; ---; n=25) injected by tumor cells (C). Number of the survival days of the sympathectomized mice (6-OHDA; ; n=25) and mice with the intact sympathetic nervous system (VEH; ; n=25) injected by B16-F10 melanoma cells (D). Value refl ecting the number of survival days is expressed as the mean±SEM and each value represents an average of 25-27 mice (Log-rank test, Student t-test). Abbreviations: 6-OHDA -6-hydroxydopamine, VEH -vehicle Inc., Germany). Diff erences between the groups were determined by Student t-test. Survival curves were analyzed according to Kaplan-Meier and the Log-rank test was used to determine diff erences in survival between groups. Th e results are expressed as means±SEM and represent an average of 25-27 animals. A value of p<0.05 was considered statistically signifi cant.
Results
Eff ect of sympathetic denervation on melanoma progression. In both experimental groups of the tumor-bearing mice (VEH and 6-OHDA), the fi rst palpable tumors were observed on the 7 th day ( Figure 3A) . In the VEH group of mice, tumors were developed on the 14 th day in all the animals injected with melanoma cells (100% incidence of tumors; Figure 3B ). In 6-OHDA group of mice, two mice injected with melanoma cells did not show tumor development (92.59% incidence of tumors; Figure  3B ) and the last tumors appeared on the 18 th day post-injection of B16-F10 melanoma cells. Significantly delayed development of palpable tumors was observed in sympathectomized mice (p=0.0219; Figure 3A ). Moreover, chemical sympathectomy also signifi cantly prolonged the survival of mice (p=0.0399; median fo r VEH: 29 days, median for 6-OHDA: 34 days; Figure 3C ). However, average number of survival days was not aff ected by sympathectomy (VEH: 33.36±2.292; 6-OHA: 40.04±2.784; t=1.835, df=50, p=0.0725; Figure 3D ).
Finally, the eff ect of the chemical sympathectomy on melanoma progression was assessed also by weighting of the developed melanoma mass. Th e weight of the developed melanoma tissue was signifi cantly increased in sympathectomized mice in comparison with animals from the VEH group (t=2.424, df=48, p=0.0192; Figure 4 ).
Discussion
Th e aim of the present study was to fi nd out whether temporal elimination of sympathetic neurotransmission, performed before tumor growth induction, may exert a long-lasting eff ect on the progression of melanoma in mice. We observed that chemical sympathectomy resulted not only in a later development of tumors, but also signifi cantly prolonged the survival of these animals compared to mice with an intact sympathetic neurotransmission. Interestingly, the weight of the melanomas was signifi cantly higher in sympathectomized mice than in mice with intact sympathetic nervous system. Clinical and experimental data have shown that sympathetic nervous system may signifi cantly potentiate the cancer progression. In support of this assumption, women with breast cancer that underwent psychological interventions reducing stress or were treated by β-blockers for hypertension, survived longer when compared to matched controls (GieseDavis et al. 2011) . Interventions aff ecting the sympathetic neurotransmission in tumor-bearing animals (e.g. sympathectomy, administration of β-blockers) have shown stimulatory eff ect of sympathetic nervous system on several experimental tumors, as well. For example, chemical sympathectomy performed by 6-OHDA attenuated the incidence of N-methyl-N´-nitro-N-nitrosoquanidine (MNNG) induced gastric cancer in rats (Tatsuta et al. 1992) , inhibited the growth pattern of LPC-1 plasmacytoma tumors in mice (Grzanna et al. 1985) , and also decreased the incidence of intra-abdominal fi brosarcoma tumors in rats and prolonged their survival (Lackovicova et al. 2011) . Similarly, bilateral surgical sympathectomy in rats resulted in the development of significantly smaller and less invasive tongue tumors than in sham-operated animals (Raju et al. 2007; Raju et al. 2009 ). Moreover, pre-treatment of tumor-bearing rats with β-blockers signifi cantly reduced the development of tumors in stressed animals as well as development of metastases aft er surgical removal of the tumor mass (Sloan et al. 2010) . Unilateral superior cervical ganglionectomy in mice with subcutaneous mammary tumor masses in an ear also attenuated the tumor growth approximately by more than 50% compared with the contralateral tumors induced in ear with intact sympathetic innervation (Romeo et al. 1991) . In their complex study, Magnon and co-workers (2013) have tested both type of sympathectomy and have found that the early phases of the prostate cancer development were prevented by chemical as well as surgical sympathetic denervations (Magnon et al. 2013) . However, it is necessary to note that not all the studies reported have attenuated the tumor Figure 4 . Tumor weight (g) in the tumor-bearing mice with the intact sympathetic nervous system (VEH; ; n=25) and the sympathectomized tumor-bearing mice (6-OHDA; ; n=25) in survival study. Each value is expressed as the mean±SEM and represents an average of 25 mice. Statistical signifi cance compar ed with VEH group: *p<0.05 (Student t-test). Abbreviations: 6-OHDA -6-hydroxydopamine, VEH -vehicle growth under conditions of reduced sympathetic transmission. However, the number of these studies is only sparse (Brenner et al. 1992; Basu et al. 2004) .
Th e eff ect of eliminated or attenuated sympathetic neurotransmission on cancer progression and metastasis formation is mediated by several mechanisms. Basu with co-workers (2004) have attributed an important role of dopamine in markedly increased growth of malignant B16 melanoma tumors in mice and suggested that dopamine might regulate malignant tumor growth by modulating angiogenesis, since blood vessels are supplied by peripheral dopaminergic nerves. On the other hand, Raju and colleagues (2007) have explained the cause of significantly smaller and less invasive tongue tumors in bilaterally sympathectomized rats by the diff erences in the sympathetic innervation pattern within and around the tumors and decreased interstitial fl uid pressure and lymph vessel area. In another study of Raju with collective (2009) , have found that sympathetic denervation signifi cantly may alter the geneexpression profi le of tumor cells. Th ey have found 280 genes diff erentially expressed in tumors with intact sympathetic innervation compared with the bilaterally sympathectomized tumors. Alterations have been found in genes associated with the cell adhesion and signalling structure, proliferation, metabolism, lymphangiogenesis, growth and development, and immunity (Raju et al. 2009 ). Similarly, we also found in melanoma tissue changes in expression profi le of many genes related to cancer-limiting processes, such as apoptosis, hypoxia, and angiogenesis, induced by chemical denervation in mice (Horvathova et al. 2016) .
In our previous study, we have shown that chemical sympathectomy may signifi cantly reduce the mass of the melanoma tissue in mice sacrifi ced 20 days aft er the injection of tumor cells (Horvathova et al. 2016) . However, it is known that chemical sympathectomy exerts only a temporal destruction of sympathetic nerve endings. Within approximately one month these nerve endings start to regenerate (Kruszewska et al. 1995) and sympathetic neurotransmission may be even exaggerated (our data, not published). Th erefore, in the present study, we investigated whether chemical sympathectomy may exert long-lasting eff ect on tumor growth. We are demonstrating a benefi cial eff ect of the elimination of the sympathetic neurotransmission on the development of melanoma and survival in mice. However, surprisingly, we observed that mass of melanoma tissue was increased in the sympathectomised mice kept for monitoring of survival. We propose that this survival might be a consequence of the noradrenergic nerve endings regeneration, which begins already 21 days aft er 6-OHDA application (Kruszewska et al. 1995) . Th is fi nding may refl ect also activation of a complex adaptation or compensation responses within the tumor microenvironment deprived of the sympathetic neurotransmitters (e.g. norepinephrine, neuropeptide Y).
Based on the above-mentioned fi ndings, we propose that attenuation of the sympathetic neurotransmission may represent a potent adjuvant therapeutic approach for the oncological patients. However, for the inhibition of tumor growth, it will be necessary to maintain the reduced sympathetic neurotransmission as long as possible. Reduced transmission of signals from sympathetic nerve endings to the cells eff ectors (e.g. tumor cells, immune cells, fi broblasts) may be utilized for blockade of the eff ects of the psychological stress that accompanies the cancer diagnosis as well as for the attenuation of the secondary metastasis development aft er surgical removal of the primary tumor mass (Andersen et al. 2007; Powe and Entschladen 2011; Neeman et al. 2012) . However, it is necessary to determine: 1) when to start with the interventions reducing the sympathetic neurotransmission and 2) for how long these therapeutic approaches in the given patient should be used.
In conclusion, experimental and clinical fi ndings support the assumption that reduction of the signalization related to sympathetic neurotransmission (e.g. administration of β-blockers, systemic or local sympathetic denervation of tumor tissues) may represent an adjuvant therapeutical approach for the oncological patients. However, tumor tissue represents highly complex system that rapidly responses to any treatment interventions (Holohan et al. 2013 ) and it can be expected that reduced sympathetic neurotransmission in the tumor microenvironment may induce several (adaptive) responses at the level of the tumor tissue and the level of the cancer cells.
